Commentary: Debridement, antibiotics and implant retention (DAIR) for the management of knee prosthetic joint infection

Shiraz A. Sabah1*, William F. M. Jackson2

1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK

2Nuffield Orthopaedic Centre, Oxford, UK


Prosthetic joint infection (PJI) is a devastating complication following knee replacement, and accounts for 0.92 (0.90-0.94) revisions per 1000 patient-years1. Recent literature has suggested that infection eradication rates may be similar between one- and two-stage procedures2. However, staged treatment is cost-intensive, carries significant morbidity and mortality and may be considered “overtreatment” in some cases2. As a result, focus has renewed on single-stage revision. However, the role of debridement, antibiotics and implant retention (DAIR) procedures have been given comparatively less attention. The main purpose of “Debridement, antibiotics and implant retention (DAIR) for the management of knee prosthetic joint infection”3 was to describe the indications for this procedure and an appropriate surgical technique. This commentary will provide a rapid review of the most important aspects of this article with reference to the literature and our own practice.

The British Orthopaedic Association (BOA) and British Association for Surgeons of the Knee (BASK) have recently produced a document outlining best practices for the investigation and management of PJI after knee replacement4. This advocates methods to standardise diagnosis, including use of a named clinical prediction rule, such as the International Consensus Meeting (ICM) 2013 criteria5. The document also lists strategies to improve the diagnostic value of microbiological sampling. Perhaps most important is the recommendation that patients are antibiotic-free for a minimum of two weeks prior to sampling, unless the patient is acutely unwell and these cannot safely be omitted. For joint aspirates, samples should be inoculated into blood culture bottles to improve culture yield, and facilities should be available to report synovial fluid leukocyte counts and granulocyte percentage to improve the interpretation of results. Bedside testing using additional markers, such as leukocyte esterase, can also be considered; however, clear benefit for combining diagnostic tests is yet to be demonstrated6. Tissue samples should also be obtained. In cases of chronic PJI, this may be prior to revision surgery – through biopsy either in the operating theatre or interventional radiology suite. We have a low threshold for re-sampling in patients with negative initial cultures and high suspicion of PJI. This includes additional testing, such as extended culture techniques or polymerase-chain reaction (PCR) assays. More commonly in acute PJI, tissue samples are obtained at the time of DAIR or revision surgery. Our practice is to obtain five surgical specimens from different anatomical locations within the knee using a non-touch technique and clean instruments for each sample. The recommendation for five (or six) microbiological samples originates from the Oxford Skeletal Infection Research and Intervention Service (OSIRIS) Collaborative, who used a simple mathematical model to evaluate the diagnostic performance of different numbers of samples7. The precise locations for sampling are decided intraoperatively, guided by the principles of sampling macroscopically abnormal tissue, providing coverage of wide area of the knee and preferentially sampling tissue in contact with the material and joint fluid8. We typically obtain samples from the bone-implant interface, suprapatellar pouch and medial and lateral gutters. The recent study by Bémer et al. reported that the rate of sample positivity showed little variation with type of tissue8. We send samples for both microbiological and histological analysis. Histological analysis is useful in cases of culture-negative PJI. Diagnosis is typically made using Feldman’s histological criteria of at least 5 neutrophils per high-power field over five separate microscopic fields9. Radiological investigations in PJI include mandatory plain radiographs to investigate for septic loosening and to check implant alignment. Specialised nuclear medicine tests are not useful in acute PJI, but may be in chronic cases. The assimilation of multiple test results is best achieved in an Infection Multidiscipinary Team (MDT) meeting involving surgeons, microbiologists, radiologists and specialist nurses.

DAIR should be considered as a treatment option for acute PJI, whether in the setting of recent surgery or haematogenous spread. Early-acute PJI has been defined as less than 3 weeks of infective symptoms, in patients within 3 months of index surgery; whilst late-acute PJI has been defined as new infective symptoms more than 3 months from index surgery in a previously asymptomatic joint replacement10. Whilst previous guidelines have recommended against DAIR after four weeks11, newer evidence suggests that the duration of symptoms may be more important12.

The pre-requisites for DAIR include a well-functioning knee that is not loose, unstable or misaligned4. Further contraindications are the presence of a sinus tract, the inability to achieve adequate wound coverage and infections caused by difficult-to-treat organisms (such as fungi or multi-drug resistant species). There is currently no agreement on the optimal timing of surgery for ‘leaky’ wounds. However, the LEAK study is a prospective, national RCT investigating early DAIR versus non-operative management for patients with persistent wound leakage at post-operative day 9 or 1013.

Simple, open or arthroscopic washout procedures should be viewed as temporising only and reserved for acutely unwell patients who would not tolerate a formal DAIR or revision procedure. Our recent article provided a detailed operative technique and emphasised the importance of involvement of an experienced arthroplasty surgeon3. The key considerations were to provide an accurate microbiological diagnosis, to maximise reduction of the burden of infection and to be able to convert to a one- or two-stage revision procedure if necessary. To improve the success of infection clearance, it is essential that surgeons are competent to perform an extensile approach and to thoroughly debride the joint. All modular components should be exchanged, and this facilitates access to the posterior knee. DAIR procedures should be allocated appropriate time on an operating list. This should account for the time required for meticulous debridement, lavage with at least 8 litres of fluid, and the need for the surgeon to re-scrub, re-prep and re-drape, and for clean instruments to be opened.

It is important to review the described surgical technique in the context of the available evidence:

Microbiological sampling using a non-touch technique with clean instruments

We consider this to be a pragmatic approach designed to minimise contamination. Whilst there is limited evidence to support this practice, this is possibly an area where theory alone provides sufficient support.

Postponement of prophylactic antibiotics until after microbiological sampling

This recommendation is likely to engender more debate. A recent systematic review by Wouthuyzen-Bakker et al.14 found that antibiotic administration at induction did reduce culture yield for a minority of patients. However, the conclusion of their review was to recommend against this practice on the basis that rates of surgical site infection (SSI) may increase. It is important to note that investigation of SSI rates was not a focus of their review. Instead, this conclusion was based on a single retrospective cohort study from their centre15. This showed that earlier surgeries (from 2007-2010) had higher rates of SSI than later surgeries (from 2010-2013), which they attributed to the timing of prophylactic antibiotic administration.

Where possible, the choice of antibiotic therapy is tailored to the susceptibility of the infecting organism. For empiric therapy, our unit favours intravenous meropenem and vancomycin since it has been shown to provide effective coverage for a broad spectrum of organisms16. These antibiotics are continued post-operatively under the stewardship of our Bone Infection Unit. Meropenem is usually discontinued at 48 hours, provided that gram-negative organisms have not been cultured. Vancomycin is continued until final culture results are available.

Volume and choice of lavage fluid and use of local bio-absorbable antibiotics

The Second International Consensus Meeting on Musculoskeletal Infections did not identify any studies which addressed the question of volume of fluid for lavage in DAIR17. However, there was a super majority, strong consensus for lavage with 6-9 litres of fluid. Future studies are required to evaluate the use of lavage agents which disrupt biofilm and the efficacy of local bio-absorbable antibiotics as an adjunct.

All patients should be enrolled in an Infection MDT to plan appropriate post-operative antimicrobial treatment and to monitor response. Patients should be counselled to expect antibiotic treatment for a period of three to six months in most cases. This typically involves initial broad-spectrum intravenous antibiotics, followed by a more targeted regimen of usually oral antibiotics based on final culture results. The duration of antibiotic administration may decrease in the future, but the current evidence-base is limited. The Second International Consensus Meeting on Musculoskeletal Infections, concluded that the optimal duration of antibiotics was unknown, but a minimum of six weeks treatment was indicated17.

In our practice, even with protocolised treatment as above, our local data suggests failure rates of 20-30% (unpublished work). Several series have demonstrated the importance of adequate debridement18 and the ability to achieve acceptable clinical outcomes following DAIR19. Wouthuyzen-Bakker et al.10 recently reported success rates of 76% for DAIR in early-acute PJI compared to 46% for late-acute PJI. The same pattern was identified by Zhu et al.20. Both studies identified that Staphylococcus aureus infection was a risk factor for failure of late-acute DAIR. In addition, the CRIME-80 score may be useful to predict failure for late acute infections22. For acute post surgery PJI, the KLIC score (Kidney, Liver, Index surgery, Cemented prosthesis and C-reactive protein value) may instead be used21. It is also of note that DAIR procedures destined to fail re-present early, with 90% of cases declaring themselves within the first year10.

There are currently no registry reports on the outcomes following DAIR. The National Joint Registry (NJR) for England, Wales, Northern Ireland and the Isle of Man have previously grouped DAIR procedures with single-stage revisions in their reports1. However, their latest data collection forms will allow these procedures to be analysed separately in the future. Few studies have evaluated patient reported outcome measures (PROMs) following DAIR procedures. However, there is emerging evidence from our unit that successful DAIR can produced similar functional outcomes to uncomplicated knee arthroplasty23.

Acceptable clinical outcomes and infection eradication can be achieved with DAIR procedures in the context of appropriate pre-operative planning, surgical technique and multidisciplinary team follow-up.

One or more authors have received Speakers Bureau fees from Zimmer Biomet and DePuy Synthes. Neither company had any role in the design, conduct or reporting of this study.

  1. National Joint Registry for England Wales Northern Ireland and the Isle of Man. NJR 17th Annual Report. 2020; (December 2019).
  2. Izakovicova P, Borens O, Trampuz A. Periprosthetic joint infection: current concepts and outlook. EFORT Open Rev [Internet]. 2019 Jul 1; 4(7): 482–94. Available from: https://doi.org/10.1302/2058-5241.4.180092
  3. Vaz K, Scarborough M, Bottomley N, et al. Debridement, antibiotics and implant retention (DAIR) for the management of knee prosthetic joint infection. Knee. 2020 Sep 17.
  4. Investigation and Management of Prosthetic Joint Infection in Knee Replacement [Internet]. [cited 2020 Oct 15]. Available from: https://www.boa.ac.uk/resources/investigation-and-management-of-prosthetic-joint-infection-in-knee-replacement.html
  5. Cats-Baril W, Gehrke T, Huff K, et al. International consensus on periprosthetic joint infection: Description of the consensus process. Clin Orthop Relat Res [Internet]. 2013 [cited 2020 Oct 15]; 471(12): 4065–75. Available from: https://pubmed.ncbi.nlm.nih.gov/24155178/
  6. Abdelbary H, Cheng W, Ahmadzai N, et al. Combination Tests in the Diagnosis of Chronic Periprosthetic Joint Infection: Systematic Review and Development of a Stepwise Clinical Decision-Making Tool. JBJS [Internet]. 9000;Latest Art. Available from: https://journals.lww.com/jbjsjournal/Fulltext/9000/Combination_Tests_in_the_Diagnosis_of_Chronic.99649.aspx
  7. Atkins BL, Athanasou N, Deeks JJ, et al. Prospective Evaluation of Criteria for Microbiological Diagnosis of Prosthetic-Joint Infection at Revision Arthroplasty. J Clin Microbiol [Internet]. 1998 Oct 1; 36(10): 2932 LP – 2939. Available from: http://jcm.asm.org/content/36/10/2932.abstract
  8. Bémer P, Léger J, Tandé D, et al. How Many Samples and How Many Culture Media To Diagnose a Prosthetic Joint Infection: a Clinical and Microbiological Prospective Multicenter Study. Forbes BA, editor. J Clin Microbiol [Internet]. 2016 Feb 1; 54(2): 385 LP – 391. Available from: http://jcm.asm.org/content/54/2/385.abstract
  9. Feldman DS, Lonner JH, Desai P, et al. The role of intraoperative frozen sections in revision total joint arthroplasty. JBJS. 1995; 77(12): 1807–13.
  10. Wouthuyzen-Bakker M, Sebillotte M, Huotari K, et al. Lower Success Rate of Débridement and Implant Retention in Late Acute versus Early Acute Periprosthetic Joint Infection Caused by Staphylococcus spp. Results from a Matched Cohort Study. Clin Orthop Relat Res [Internet]. 2020 Jun 1 [cited 2020 Oct 19]; 478(6): 1348–55. Available from: https://pubmed.ncbi.nlm.nih.gov/32106134/
  11. Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: Clinical practice guidelines by the infectious diseases Society of America. Clin Infect Dis. 2013; 56(1).
  12. Löwik CAM, Parvizi J, Jutte PC, et al. Debridement, Antibiotics, and Implant Retention Is a Viable Treatment Option for Early Periprosthetic Joint Infection Presenting More Than 4 Weeks After Index Arthroplasty. Clin Infect Dis [Internet]. 2020 Jul 27; 71(3): 630–6. Available from: https://doi.org/10.1093/cid/ciz867
  13. Lowik CAM, Wagenaar FC, van der Weegen W, et al. LEAK study: design of a nationwide randomised controlled trial to find the best way to treat wound leakage after primary hip and knee arthroplasty. BMJ Open [Internet]. 2017; 7(12): e018673. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med14&AN=29288184 http://oxfordsfx.hosted.exlibrisgroup.com/oxford?sid=OVID:medline&id=pmid:29288184&id=doi:10.1136%2Fbmjopen-2017-018673&issn=2044-6055&isbn=&volume=7&issue=12&spage=e01
  14. Wouthuyzen-Bakker M, Benito N, Soriano A. The effect of preoperative antimicrobial prophylaxis on intraoperative culture results in patients with a suspected or confirmed prosthetic joint infection: A systematic review. J Clin Microbiol. 2017; 55(9): 2765–74.
  15. Wouthuyzen-Bakker M, Tornero E, Claret G, et al. Withholding Preoperative Antibiotic Prophylaxis in Knee Prosthesis Revision: A Retrospective Analysis on Culture Results and Risk of Infection. J Arthroplasty [Internet]. 2017 Sep 1 [cited 2020 Dec 3]; 32(9): 2829–33. Available from: http://www.arthroplastyjournal.org/article/S0883540317303017/fulltext
  16. Dudareva M, Hotchen AJ, Ferguson J, et al. The microbiology of chronic osteomyelitis: Changes over ten years. J Infect. 2019 Sep; 79(3): 189–98.
  17. Argenson JN, Arndt M, Babis G, et al. Hip and Knee Section, Treatment, Debridement and Retention of Implant: Proceedings of International Consensus on Orthopedic Infections. J Arthroplasty [Internet]. 2019 Feb 1; 34(2): S399–419. Available from: https://doi.org/10.1016/j.arth.2018.09.025
  18. Johns BP, Loewenthal MR, Davis JS, et al. Open Debridement is Superior to Arthroscopic Debridement for the Infected Total Knee Arthroplasty. J Arthroplasty [Internet]. 2020 [cited 2020 Oct 19]; Available from: https://pubmed.ncbi.nlm.nih.gov/32713724/
  19. Ottesen CS, Troelsen A, Sandholdt H, et al. Acceptable Success Rate in Patients With Periprosthetic Knee Joint Infection Treated With Debridement, Antibiotics, and Implant Retention. J Arthroplasty [Internet]. 2019 Feb 1 [cited 2020 Oct 19]; 34(2): 365–8. Available from: https://pubmed.ncbi.nlm.nih.gov/30401558/
  20. Zhu MF, Kim K, Cavadino A, et al. Success Rates of Debridement, Antibiotics, and Implant Retention in 230 Infected Total Knee Arthroplasties: Implications for Classification of Periprosthetic Joint Infection. J Arthroplasty [Internet]. 2020 [cited 2020 Oct 19]; Available from: https://pubmed.ncbi.nlm.nih.gov/32868114/
  21. Tornero E, Morata L, Martínez-Pastor JC, et al. KLIC-score for predicting early failure in prosthetic joint infections treated with debridement, implant retention and antibiotics. Clin Microbiol Infect. 2015; 21(8): 786-e9.
  22. Wouthuyzen-Bakker M, Sebillotte M, Lomas J, et al. Clinical outcome and risk factors for failure in late acute prosthetic joint infections treated with debridement and implant retention. J Infect. 2019; 78(1): 40–7.
  23. Alvand A, Grammatopoulos G, DeVos F, et al. Ten-year outcome of debridement, antibiotics and implant retention in knee periprosthetic joint infection. In AAOS 2017 Annual Meeting 2017. Available from: http://aaos2017.conferencespot.org/aaos63877-1.3443042/t002-1.3449455/f002-1.3449456/a027-1.3450355/472-1.3450366
 

Article Info

Article Notes

  • Published on: December 21, 2020

Keywords

  • Prosthetic joint infection
  • Debridement
  • Antibiotics
  • implant retention
  • Revision
  • Total knee replacement

*Correspondence:

*Dr. Shiraz A. Sabah
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK
Email: shiraz.sabah@ndorms.ox.ac.uk.